Treatment options for HUS secondary to Escherichia coli O157:H7

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Renal manifestations in Fabry disease and therapeutic options

Anemia management in chronic kidney disease

Approach to diagnosis of infective endocarditis

Volume 83, Issue 3, Pages (March 2013)

Shining light on vitamin D trials in chronic kidney disease

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Volume 80, Issue 10, Pages (November 2011)

Recent outbreak of hemolytic uremic syndrome in Germany

John P. Middleton, Patrick H. Pun Kidney International

Need for better diabetes treatment for improved renal outcome

Training for the infectious diseases speciality in Norway

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 70, Pages S21-S25 (December 2006)

Treatment options for HUS secondary to Escherichia coli O157:H7

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

Laboratory diagnosis of Clostridium difficile disease

The epidemiology of chronic kidney disease

Volume 87, Issue 2, Pages (February 2015)

Edmund G. Lowrie Kidney International

Study of Heart and Renal Protection (SHARP)

Infected glomerulus Kidney International

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

New insights in uremic toxins

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 85, Issue 5, Pages (May 2014)

Microbiology and outcomes of peritonitis in North America

Volume 74, Issue 8, Pages (October 2008)

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

AGEs in foods: Do they play a role in uremia?

Extracorporeal removal of toxins

Nitric oxide, oxidative stress, and apoptosis

Nephrology Crossword: Glomerulonephritis

Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson Kidney International

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Hydrogen: another gas with therapeutic potential

A man with a hole in his penis

Prehypertension: is it relevant for nephrologists?

Homocysteine, renal function, and risk of cardiovascular disease

Vitamin D in chronic kidney disease: is the jury in?

Volume 82, Issue 9, Pages (November 2012)

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Clinical benefits of slowing the progression of renal failure

Volume 55, Pages S3-S16 (June 1999)

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Is it the low-protein diet or simply the salt restriction?

Charles A. Herzog Kidney International

Volume 76, Issue 1, Pages 8-10 (July 2009)

Renal prognosis of toxigenic Escherichia coli infection

Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller

Volume 75, Issue 7, Pages (April 2009)

Victoria R. Briggs, Badri M. Shrestha, Martin E. Wilkie

Membranous nephropathy: recent travels and new roads ahead

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Antioxidant therapy in hemodialysis patients: a systematic review

Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?

Volume 74, Issue 10, Pages (November 2008)

Volume 75, Issue 8, Pages (April 2009)

The cost of starting and maintaining a large home hemodialysis program

Sugar-sweetened beverages and chronic disease

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Treatment options for HUS secondary to Escherichia coli O157:H7 Martin Bitzan Kidney International Volume 75, Pages S62-S66 (February 2009) DOI: 10.1038/ki.2008.624 Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 1 Clinical spectrum and evolution of infections by Shiga toxin-producing Escherichia coli. Arrow thickness indicates the risk or likelihood of that particular outcome. Kidney International 2009 75, S62-S66DOI: (10.1038/ki.2008.624) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 2 Schematic diagram depicting the pathogenesis of Shiga toxin-producing Escherichia coli disease and putative interventions. LPS (lipopolysaccharide), Stx (Shiga toxin), STmAb (Stx-neutralizing monoclonal antibody), SAPK (stress-activated protein kinase [p38, JNK]). The numbers refer to therapeutic categories (see text). Kidney International 2009 75, S62-S66DOI: (10.1038/ki.2008.624) Copyright © 2009 International Society of Nephrology Terms and Conditions